What is B. Riley’s Estimate for Cytokinetics Q1 Earnings?

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Cytokinetics in a report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of ($1.46) per share for the quarter. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.34) EPS and FY2029 earnings at $1.06 EPS.

A number of other analysts also recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a report on Thursday, February 6th. Citigroup assumed coverage on shares of Cytokinetics in a report on Friday, February 7th. They issued a “buy” rating and a $86.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a report on Friday, February 28th. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a report on Friday, February 7th. Finally, Mizuho boosted their price objective on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Stock Performance

Shares of CYTK stock opened at $43.88 on Thursday. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of -8.16 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The company has a 50-day simple moving average of $47.00 and a 200 day simple moving average of $51.03. Cytokinetics has a 52 week low of $40.53 and a 52 week high of $75.71.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.26 million.

Institutional Trading of Cytokinetics

Hedge funds have recently modified their holdings of the business. Jones Financial Companies Lllp lifted its stake in Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares during the period. MetLife Investment Management LLC grew its holdings in shares of Cytokinetics by 0.4% in the third quarter. MetLife Investment Management LLC now owns 123,308 shares of the biopharmaceutical company’s stock valued at $6,511,000 after purchasing an additional 538 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Cytokinetics by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company’s stock worth $6,750,000 after buying an additional 565 shares during the period. Arizona State Retirement System boosted its stake in shares of Cytokinetics by 1.9% during the fourth quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company’s stock valued at $1,522,000 after purchasing an additional 600 shares during the period. Finally, Inspire Investing LLC raised its holdings in shares of Cytokinetics by 7.8% in the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 616 shares in the last quarter.

Insider Transactions at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.64, for a total value of $369,672.00. Following the completion of the transaction, the executive vice president now owns 116,071 shares in the company, valued at $5,877,835.44. This trade represents a 5.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wendall Wierenga sold 742 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $48.61, for a total transaction of $36,068.62. Following the completion of the transaction, the director now owns 24,559 shares of the company’s stock, valued at $1,193,812.99. This trade represents a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,822 shares of company stock worth $874,048 over the last three months. 3.40% of the stock is owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.